Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/23
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant GliomaGlobeNewsWire • 08/08/23
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern TimeGlobeNewsWire • 08/07/23
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of DirectorsGlobeNewsWire • 07/11/23
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual ConferenceGlobeNewsWire • 06/12/23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/23
Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern TimeGlobeNewsWire • 05/02/23
Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer ProgramGlobeNewsWire • 04/20/23
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 04/18/23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/23
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern TimeGlobeNewsWire • 03/23/23
Lisata Therapeutics Announces Participation in Upcoming Conferences in FebruaryGlobeNewsWire • 02/01/23
Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022GlobeNewsWire • 11/07/22
Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022GlobeNewsWire • 10/06/22